Molecular diagnostics of prostate cancer: impact of molecular tests

Prostate cancer (PCa) is the second leading cause of cancer-related death among men. Prostate-specific antigen (PSA) testing is used in screening programs for early detection with a consequent reduction of PCa-specific mortality at the cost of overdiagnosis and overtreatment of the nonaggressive PCa. Recently, several assays have been commercially developed to implement PCa diagnosis, but they have not been included in both screening and diagnosis of PCa. This review aims to describe the actual and novel commercially available molecular biomarkers that can be used in PCa management to implement and tailor the screening and diagnosis of PCa.

• Publication year

  2024

• Venue

  Asian Journal of Andrology

• Publication date

  2024-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/aja202411PMID 38738960PMCID 11614165
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of Aggressive Prostate Cancer at Diagnosis

  2023cited by this paper
• A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy.

  2023cited by this paper
• Guidelines for genetic testing in prostate cancer: a scoping review

  2023cited by this paper
• ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

  2023cited by this paper
• PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness

  2023cited by this paper
• Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer

  2023cited by this paper
• Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy

  2023cited by this paper
• Relationship between Proclarix and the Aggressiveness of Prostate Cancer

  2023cited by this paper
• Combination of PI-RADS score and mRNA urine test—A novel scoring system for improved detection of prostate cancer

  2022cited by this paper
• Tissue immunostaining of candidate prognostic proteins in metastatic and non-metastatic prostate cancer

  2022cited by this paper
• How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.

  2022cited by this paper
• An appraisal of genetic testing for prostate cancer susceptibility

  2022cited by this paper
• Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

  2022cited by this paper
• Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis

  2022cited by this paper
• Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy

  2022cited by this paper
• Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach

  2022cited by this paper
• Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study.

  2022cited by this paper
• Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer

  2022influential reference
• Evaluation of Phi Clinical Performance for the Detection of Prostate Cancer in Routine Clinical Practice.

  2021cited by this paper
• Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?

  2021cited by this paper
• IsoPSA® Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/ml: A Real-World Observational Clinical Utility Study

  2021cited by this paper
• Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need.

  2021cited by this paper
• Editorial Comment.

  2020cited by this paper
• Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma

  2020cited by this paper
• Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.

  2020cited by this paper
• Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer

  2020cited by this paper
• Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer

  2020cited by this paper
• Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2020cited by this paper
• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.

  2020cited by this paper
• Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy.

  2020cited by this paper
• Genomic and phenotypic heterogeneity in prostate cancer

  2020cited by this paper
• Overdiagnosis and lives saved due to reflex testing men with intermediate prostate-specific antigen levels.

  2019cited by this paper
• A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

  2018cited by this paper
• Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men

  2018cited by this paper
• Markers and Immunoprofile of Male Genital Tract Tumors

  2018cited by this paper
• Biomarkers for Diagnosis and Prognosis of Prostate Cancer

  2018cited by this paper
• NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.

  2018cited by this paper
• Prostate cancer: diagnostic criteria and role of immunohistochemistry

  2018influential reference
• Urinary biomarkers of prostate cancer

  2018cited by this paper
• Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy.

  2017cited by this paper
• Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

  2017cited by this paper
• Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting

  2017cited by this paper
• Clinically available RNA profiling tests of prostate tumors: utility and comparison

  2016cited by this paper
• The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.

  2016cited by this paper
• The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients

  2016cited by this paper
• Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis

  2016cited by this paper
• Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.

  2015cited by this paper
• Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

  2015cited by this paper
• Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.

  2014cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013influential reference
• Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer

  2013cited by this paper
• The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

  2012influential reference
• Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

  2008cited by this paper

• Epigenetic and Liquid Biopsy Biomarkers in Prostate Cancer: Bridging Tumor Heterogeneity and Clinical Implementation

  2026cites this paper
• Evaluating the Diagnostic Role of the Testosterone-to-Prostate-Specific Antigen Ratio in Pre-Biopsy Risk Stratification of Prostate Cancer

  2025cites this paper
• The continued pursuit of new strategies and new technologies

  2024cites this paper